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Abstract
Introduction: The authors present their personal experience in 
qualifying and treating adult patients using veno-arterial (VA) 
extracorporeal membrane oxygenation (ECMO) in postcardi-
otomy cardiogenic shock.
Aim: The aim of this study was to analyze the results of VA 
ECMO in patients with postcardiotomy cardiogenic shock. An 
analysis of the risk factors of postoperative mortality was also 
performed.
Material and methods: We analyzed the perioperative results 
of survivors and non-survivors of treatment using VA ECMO. 
We compared the number of days on VA ECMO therapy, types 
of cardiac surgical procedures, and the frequency of VA ECMO 
complications such as coagulation disorders, lower limb isch-
emia, cardiac tamponade, and renal replacement therapy.
Results: There were 27 patients treated with VA ECMO dur-
ing the study period. The mean patient age was 45 ±16 years. 
The hospital mortality rate of patients treated with VA ECMO 
therapy was 70% (19/27). There were no significant differences 
between the groups of survivors and non-survivors regarding 
age, gender, admission type and coexisting diseases. Type of 
cardiac surgical procedure had no influence on mortality or 
complications of therapy using VA ECMO.
Conclusions: The VA ECMO can be an effective form of therapy 
in some patients in postcardiotomy cardiogenic shock.
Key words: postcardiotomy cardiogenic shock, extracorporeal 
membrane oxygenation.
Streszczenie
Wstęp: Autorzy przedstawiają doświadczenia własne w kwa-
lifikowaniu i prowadzeniu terapii dorosłych pacjentów we 
wstrząsie kardiogennym po operacjach serca, u których za-
stosowano membranowe natlenianie pozaustrojowe (ECMO) 
w konfiguracji żylno-tętniczej.
Cel: Głównym celem badania było przeprowadzenie analizy 
wyników leczenia pacjentów w ciężkim wstrząsie kardiogen-
nym po operacjach kardiochirurgicznych leczonych z użyciem 
VA ECMO. Autorzy dokonali analizy czynników mających 
wpływ na przeżycie pacjentów leczonych VA ECMO.
Materiał i metody: Przeanalizowano przebieg leczenia z uży-
ciem VA ECMO u pacjentów w pokardiotomijnym wstrząsie 
kardiogennym poprzez porównanie grupy pacjentów, u któ-
rych leczenie zakończyło się pomyślnie, z grupą osób, które 
zmarły pomimo zastosowania VA ECMO. Analizie poddano 
liczbę dni terapii z użyciem VA ECMO, rodzaj operacji kardio-
chirurgicznej, a także częstość wystąpienia powikłań VA ECMO, 
takich jak zaburzenia krzepnięcia, niedokrwienie kończyn dol-
nych, tamponada serca i terapia nerkozastępcza. Do badania 
włączono wszystkich kolejnych chorych leczonych w naszym 
ośrodku, znajdujących się w pokardiotomijnym wstrząsie kar-
diogennym, u których zastosowano VA ECMO.
Wyniki: W badaniu wzięło udział 27 pacjentów poddanych te-
rapii VA ECMO. Średni wiek chorych wynosił 45 ±16 lat, a śmier-
telność szpitalna – 70% (19/27). W badaniu nie stwierdzono 
znaczących różnic pomiędzy grupą zmarłych pacjentów a grupą 
osób, u których leczenie zakończyło się pomyślnie, w zakresie 
wieku, płci, trybu przyjęcia oraz chorób towarzyszących. Rodzaj 
procedury chirurgicznej nie miał istotnego wpływu na śmiertel-
ność i powikłania terapii z użyciem VA ECMO.
Wnioski: Membranowe natlenianie pozaustrojowe w konfigu-
racji żylno-tętniczej jest skuteczną formą leczenia niektórych 
pacjentów w ciężkim wstrząsie kardiogennym po operacjach 
kardiochirurgicznych.
Słowa kluczowe: pokardiotomijny wstrząs kardiogenny, mem-
branowe natlenianie pozaustrojowe.
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Introduction
Extracorporeal membrane oxygenation (ECMO), is 
a modified form of extracorporeal circulation used dur-
ing heart surgery. Depending on the configuration (veno-
venous or veno-arterial), ECMO enables prolonged sup-
port for a patient’s respiratory or cardiovascular system 
while in an intensive care unit, or provides complete re-
placement of the respiratory system. It is reported that 
0.2–6.0% of adult patients subjected to cardiac surgery 
procedures suffer from postcardiotomy cardiogenic shock 
(PCCS) [1, 2]. This occurs in patients with either low or 
acceptable ejection fraction from the left ventricle and 
who are qualified for heart surgery operations. The PCCS 
occurs not only in patients who cannot be weaned from 
cardiopulmonary bypass while in the operating room but 
also in those who show “low cardiac output syndrome” 
(LCOS) in the early postoperative period. Despite maxi-
mum inotropic stimulation, persistent hemodynamic in-
stability necessitates consideration of the use of direct 
mechanical support.
Conducting a complete surgical procedure is a prerequi-
site in this situation. Support systems, such as ECMO, ensure 
maintenance of flow in the systemic and/or pulmonary cir-
culation systems while unburdening the heart. The decision 
to cease further increase of pharmacological stimulation and 
use mechanical devices should be taken prior to hypoperfu-
sion of individual organs caused by prolonged low cardiac 
output, which leads to irreversible changes [3]. Extracorpo-
real life support (ECLS) such as ECMO may constitute an effi-
cient method of therapy for patients with severe cardiogenic 
shock, and can be used as a bridge for treatment, transplan-
tation, or long-term cardiac support therapies [4]. 
Not every patient can be subjected to ECMO treatment. 
The exclusion group includes those who have experienced 
irreversible changes causing cardiovascular or cardiopul-
monary failure, have an active hemorrhage or have con-
traindications for chronic heparinization. In some centers 
exclusion criteria include terminal treatment, uncontrolled 
malignant tumor growth, severe neurological damage, age 
above 80, and any other severe medical problem preventing 
the patient’s recovery and constituting absolute contraindi-
cations for the use of ECMO [5]. Technical contraindications 
include aortic dissection and severe aortic regurgitation [6].
Aim
The objective of this study was to analyze the results 
of VA ECMO therapy in patients with postcardiotomy car-
diogenic shock. An analysis of postoperative mortality risk 
factors was also performed.
Material and methods
Study group
The study was conducted in accordance with the Decla-
ration of Helsinki. A registered study without collection of 
personal data of patients and without an influence on the 
therapeutic process does not require an application and 
acceptance of the local Ethics Committees. Permission for 
preparation of the present manuscript was obtained from 
the management of the local hospital. This retrospective 
observational study included consecutive patients with 
PCCS treated at the Unit of Anesthesiology and Intensive 
Care of the Department of Cardiovascular Surgery and 
Transplantology of the Jagiellonian University in Krakow, 
for whom VA ECMO was used as a support system for the 
lungs and heart. A group of 25 patients treated with VA 
ECMO for accidental hypothermia and 16 patients treated 
with VA ECMO for cardiogenic shock where the etiology of 
the cardiogenic shock was different than acute heart fail-
ure after cardiac surgery were excluded from our study.
The final analysis involved a group of 27 patients treated 
from February 2009, when ECMO therapy was first used at 
our clinic, to June 2016. The analysis covered demographic 
data, type of hospital admission, primary reason for incep-
tion of the ECMO therapy, coexisting diseases, left ventricle 
ejection fraction at admission, hospital stay, intensive care 
stay time, ECMO therapy stay, mortality, and complications 
during ECMO therapy.
Hospital mortality was defined as death that occurred 
due to any cause within 30 days after the introduction of 
ECMO therapy or that occurred in a period longer than 
30 days, but during the same hospitalization period [7]. Re-
nal insufficiency was diagnosed if the creatinine level ex-
ceeded 177 μmol/l [8].
Therapy rules
The femoral vessels (vein and artery) were cannulated 
with 22–24 F outflow cannulae and 19–21 F inflow cannulae 
(Bioline Coating Maquet, Germany). The vital function sup-
port system included Rotaflow Control Console REF 706037 
(Maquet, Germany), Heater Unit HU 35 (Maquet, Germa-
ny), and a set of cannulae with the oxygenator Permanent 
Life Support Set “Bioline Coating” (Maquet, Germany). The 
support was initiated with a flow rate of 65 ml/kg/min. 
The flow was then regulated to obtain oxygenation of the 
mixed venous blood with mixed venous oxygen saturation 
(SvO2) at a level of 60–70%. Fraction of inspired oxygen 
(FiO2) was carried out at a level of 40–60 ml to obtain oxy-
gen pressure in arterial blood (pO2) within a range of 150– 
200 mm Hg, and carbon dioxide pressure (pCO2) of 35– 
45 mm Hg. Activated coagulation time (ACT) was main-
tained for 160–200 s with continuous heparin infusion. Av-
erage blood pressure was maintained at 60 mm Hg.
Control echocardiographic examinations were performed 
during the immediate postoperative period to evaluate the 
left ventricle ejection fraction (LVEF). Hemoglobin level was 
maintained at 8 mg/dl. To achieve this, transfusion of blood 
products was carried out. Platelet count was maintained 
> 80,000. A constant infusion of fentanyl with midazolam 
was used for analgosedation with concomitant use of con-
trolled lung protective ventilation (tidal volume 6 ml/kg of 
standard weight, ventilation rate 10/min, positive end-expi-
ratory pressure (PEEP) 4 cm H2O). Antibiotic treatment was 
carried out in cooperation with the hospital infection team.
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Statistical analysis
Categorical variables were expressed as counts and 
percentages. A logistic regression model was used for the 
analysis of the relationship between qualitative and contin-
uous variables with mortality. We constructed an analysis 
of the variance model. The groups studied were too small 
to perform multivariable analysis of variances. For each 
significant factor, the individual odds ratio was calculated 
with its 95% confidence interval. Wherever it was impos-
sible to use the logistic regression model, the χ2 statistic 
was calculated. A p-value less than 0.05 was considered 
an indication of a statistically significant result. Student’s 
t-test was used for the comparison of two samples and the 
non-parametric Mann-Whitney U test in the case of lack 
of normality. All statistical analyses were performed using 
Statistica 10 PL software. 
Results
The population studied included 27 PCCS patients treat-
ed with VA ECMO therapy. The average patient age was 45 
±16 years; 19 (70%) patients were male and 8 (30%), were 
female. The hospital mortality rate was 70% (19 patients).
An analysis of the factors influencing the survival of 
patients treated with VA ECMO was conducted. The sur-
vival rate was 30% (8 patients) from the group of patients 
treated with VA ECMO therapy. Patients’ demographic data 
and preoperative characteristics are presented in Table I.
The reason for the introduction of ECMO therapy in VA 
configuration was severe PCCS and lack of possibility to stop 
extracorporeal circulation after heart surgery. The types of 
cardiac surgery resulting in PCCS are presented in Table II.
There was no differences between the group of de-
ceased and the group of survivors with reference to age, 
sex, height, admission type, coexisting diseases, or left 
ventricle ejection fraction level evaluated during hospital 
admission. Using the logistic regression model to deter-
mine the relationship between qualitative and continuous 
variables, no significant relationship with reference to sex, 
age (Tab. III) or type of cardiac surgery procedure (Tab. IV) 
was observed. The hospital and Intensive Care Unit length 
of stay and VA ECMO therapy were all considerably longer 
in the group of survivors.
Using Student’s t-test and the nonparametric Mann-
Whitney U test in the case of lack of normality, the group 
of surviving patients was compared with the group of de-
ceased patients (Tab. V). The number of days of VA ECMO 
therapy, hospitalization time, and intensive care unit length 
of stay were also analyzed. Also here, the group of surviving 
patients was characterized by a considerably longer inten-
sive care unit stay (p = 0.002), hospital stay (p = 0.001), and 
number of days of ECMO therapy (p = 0.035).
In both groups, the introduction of the VA ECMO sys-
tem was not without complications (Tab. VI). In the groups 
tested the following conditions were observed: coagulation 
disorders and the need for blood product transfusion in 59% 
(16 patients), acute renal failure and the need to use continu-
ous renal replacement therapies in 44% (12 patients), and 
lower limb ischemia in 26% (7 patients). In 12 (44%) patients 
heart tamponade occurred. Surgical revision (rethoracoto-
my) due to tamponade or bleeding was performed in 56% 
(15 patients). Endocavitary electrode was needed in 37% 
(10 patients). There was no significant relationship between 
death and the complications presented above (Tab. VII).
Tab. I. Patients’ demographics and preoperative characteristics
Parameter Patients 
who died
Patients 
who survived 
P-value
Sex (M/F) 14/5 5/3 0.658
Age [years] 45.3 ±15.7 43.9 ±16.8 0.825
AH (1/0) 12/7 5/3 0.651
DM t2 (1/0) 4/15 2/6 0.594
MI (1/0) 4/15 1/7 0.528
PCI (1/0) 3/16 1/8 0.532
Urgent admission (1/0) 9/10 3/5 0.696
LVEF at admission
(median)
35.6 ±20.5
(50)
27.1 ±26.6
(45)
0.245
AH – arterial hypertension, DM t2 – diabetes mellitus type 2, MI – myocardial in-
farction, PCI – percutaneous coronary interventions, LVEF – left ventricular ejection 
fraction.
Tab. II. Type of cardiac surgery procedures 
Procedure Number 
of cases
Frequency 
(%)
Aortic valve replacement 7 26
Ascending aortic aneurysm operation 7 26
Mitral valve replacement 6 22
Heart transplantation 2 7
Pulmonary valve replacement 2 7
Left ventricular aneurysm operation 1 4
Aortic and mitral valve replacement 1 4
Pulmonary embolism 1 4
Tab. III. Logistic regression analysis of demographic variables in-
fluencing death of patient subjected to VA ECMO therapy
Parameter OR 95% CI P-value
Sex 1.68 0.3–10.7 0.563
Age 1.01 0.1–1.1 0.825
Number of days on ECMO therapy 0.9 0.9–0.8 0.065
OR – odds ratio, 95% CI – 95% confidence interval.
Tab. IV. Logistic regression analysis of risk factors influencing 
death of patient subjected to VA ECMO therapy (independent vari-
ables in the model were types of surgical procedures)
Variable OR 95% CI P-value
MvR 0.3 0.1–2.3 0.228
AvR 0.4 0.1–3.0 0.379
AAAsc 3.2 0.3–36.5 0.319
Pulmonary valve repl. 0.0 0.2–1.1 0.998
MvR – mitral valve replacement, AvR – aortic valve replacement, AAAsc – aneu-
rysm ascendancing aorta, OR – odds ratio, 95% CI – 95% confidence interval.
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Discussion
The primary message of our study is that VA ECMO was 
an effective therapy for 30% of our patients with severe 
PCCS. The hospital mortality rate of patients treated with 
VA ECMO therapy in our study was 70%. In all patients, 
the reason for the decision to introduce VA ECMO therapy 
was the lack of possibility to stop extracorporeal circulation 
after completion of the cardiosurgical procedure, despite 
optimum inotropic support. 
For our patients, the VA ECMO therapy was implanted in 
the immediate postoperative period, prior to the transfer of 
patients to the intensive care unit. The decision to introduce 
ECMO therapy was taken when the doses of pressor drugs 
approached the following levels: epinephrine: 0.3–0.5 μg/ 
kg/min, norepinephrine: 0.3–0.4 μg/kg/min, dobutamine: 
5–10 μg/kg/min. In 2 patients, the therapy was introduced 
on days 1 and 2 following intensive care unit admission, after 
ineffective attempts of hemodynamic stabilization with ino-
tropic support and after the application of an intra-aortic bal-
loon pump. In both cases, the decision to start ECMO therapy 
was triggered by a dynamic drop of heart ejection fraction 
to a value of 5–10% and elevated pressor amines demand.
Mechanical cardiac supports (MCS) is intended to 
bridge the patient to recover, or if not possible, as a bridge 
to transplantation or evaluation of alternative strategies. 
Different types of MCS systems are currently available to 
treat PCCS [9–13]. They include centrifugal pumps implant-
ed as left ventricular assist systems [14, 15] and complex 
and expensive ventricular assist devices (VAD) [5]. The re-
sults of experiences with these different devices are not 
comparable as the data are usually limited, monocentric, 
and retrospectively collected [15].
Our survival results were consistent with the results of 
published literature. Collective data from the ELSO register 
demonstrate that survival of adult patients with cardio-
genic shock is 39% [16]. Similar results were reported by Ko 
et al. [17] and Aissaoui et al. [18]. Hsu et al. and Rastan et 
al. reported that the successful weaning rate of ECMO for 
PCCS ranges from 31% to 60%, but the in-hospital mortality 
rate was 59–84% [2, 19]. 
The ECMO is also associated with various important 
morbidities. Severe hemorrhage is a frequent and chal-
lenging complication leading to the need for reoperation 
and necessity of massive transfusion of blood products. In 
our study, massive bleeding and the need for blood product 
transfusions occurred in 59% of the patients. Lower limb 
ischemia on the side of the cannulated femoral artery is de-
scribed as a complication and was found in 20% of the pa-
tients [20]. However, due to the concerns of infection and 
hemorrhage complications of the mediastinum, peripheral 
VA ECMO is preferred at our center. According to our obser-
vations, lower limb ischemia occurred in a slightly higher 
percentage of patients (26%).
There are several extracorporeal circulation support sys-
tems for patients with PCCS; however, ECMO can function 
based on access to peripheral vessels and relatively liberal 
requirements for anticoagulation. The system is mobile 
and can be used for a longer period of time and can even 
be moved with the patient. It ensures good control and flu-
ency of supporting respiratory and circulatory parameters 
[4]. The VA ECMO can successfully be used for PCCS treat-
ment when conventional therapy proves ineffective.
Limitations of the study
Firstly, it was a retrospective study. The data were ob-
tained from medical documentation. Secondly, the small 
size of the study group constitutes a significant limitation, 
and thus conclusions of statistical significance should be 
drawn with care. However, in spite of the small group of 
patients examined, certain useful, clinical trends can be ob-
served from the study.
Conclusions
The VA ECMO can be an effective form of therapy for 
some patients in postcardiotomy cardiogenic shock. How-
Tab. V. Length of ECMO therapy, intensive care unit and length of 
hospital stay for surviving and deceased groups
Parameter Patients 
who died
Patients 
who survived
P-value
Length of ECMO 
therapy [days]
(median)
7.16 ±6.04
(6)
13.00 ±7.37
(12.5)
0.035
Intensive care length 
of stay [days]
(median)
11.58 ±13.64
(6)
35.13 ±15.91
(30)
0.002
Hospital length of 
stay [days]
(median)
14.42 ±14.59
(9)
48.25 ±19.02
(48.5)
0.001
Tab. VI. Perioperative complications
Complication Number of cases Frequency (%)
Coagulation disorders 16 59
Lower limb ischemia 7 26
Rethoracotomy 15 56
Heart tamponade 12 44
Epicardial electrode 10 37
CVVHD 12 44
CVVHD – continuous veno-venous hemodialysis.
Tab. VII. Logistic regression analysis of mortality risk factors. Com-
plications of the ECMO therapy are independent variables in the 
model
Variable OR 95% CI P-value
Coagulation disorders 1.7 0.3–9.9 0.527
Lower limb ischemia 1.1 0.1–7.9 0.943
Rethoracotomy 0.7 0.1–3.9 0.638
Heart tamponade 0.7 0.1–4.2 0.707
Epicardial electrode 1.0 0.2–5.9 0.974
CVVHD 0.7 0.1–4.2 0.707
CVVHD – continuous veno-venous hemodialysis, OR – odds ratio, 95% CI – 95% 
confidence interval.
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ever, mortality in this group of patients still remains high 
even with this sophisticated form of therapy.
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